阿托伐他汀对动脉硬化性脑梗死患者NIHSS评分及超敏C反应蛋白、IL-6的影响  

Clinical effect of atorvastatin on NIHSS score as well as high sensitivity C-reactive protein and IL-6 of the patients with atherosclerotic cerebral infarction

作　　者：梁雁[1] 吴泳[1] 梁汉周[1] 万里飞[1] 

机构地区：[1]广东省高州市人民医院神经内科,广东高州525200

出　　处：《广东医学院学报》2016年第3期235-237,共3页Journal of Guangdong Medical College

摘　　要：目的探讨阿托伐他汀治疗动脉硬化性脑梗死的临床效果及其对患者炎症因子的影响。方法 90例动脉硬化性脑梗死患者随机分为观察组与对照组,每组45例。对照组予常规治疗,观察组在对照组基础上加用阿托伐他汀治疗,2周为1疗程。观察两组患者治疗前后神经功能、超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)水平的变化情况。结果两组患者治疗3、6个月后美国国立卫生研究院卒中量表(NIHSS)评分较治疗前降低,且以观察组更为显著(P<0.05)。两组患者治疗后hs-CRP和IL-6水平较治疗前降低,且以观察组更显著(P<0.05)。结论应用阿托伐他汀治疗动脉硬化性脑梗死可明显改善患者的神经功能,控制炎症因子,值得推广应用。Objective To investigate clinical effect of atorvastatin in the treatment of atherosclerotic cerebral infarction and its impact on inflammatory factors of the patients. Methods 90 cases with arteriosclerotic infarction patients admitted were randomly divided into Observation Group and Control Group with 45 cases in each group. Control Group received conventional treatment while Observation Group received treatment with atorvastatin on the basis of conventional treatment for a course of two weeks. The changes in neurological function, high sensitivity C-reactive protein （hs-CRP） and IL-6 of the two groups before and after treatment were observed. Results After a treatment of 3 and 6 months, the NIHSS score of two groups was decreased compared with that before the treatment, and Observation Group showed a more significant decrease （P〈0.05）. After treatment, the hs-CRP and IL-6 level of the two groups were decreased compared with those before the treatment, and Observation Group showed a more significant decrease （P〈0.05）. Conclusion The application of Atorvastatin in the treatment of atherosclerotic cerebral can significantly improve neurological function and control inflammatory factors, which is worth promotion.

关 键 词：脑梗死 神经功能 炎症因子 阿托伐他汀 

分 类 号：R743.3[医药卫生—神经病学与精神病学]